How many employees does Sanofi have?

As of Wed, 29 Apr 2026, Sanofi has approximately 10,001+ employees employees.

How much website traffic does Sanofi receive?

Sanofi receives about 917K monthly website visits in the latest Datakart source snapshot. This helps benchmark market attention, demand generation, and digital reach.

Is Sanofi currently hiring?

Sanofi has 1.3K open roles in the latest source snapshot. Open job volume can indicate team expansion, budget movement, and active buying needs by department.

What technologies does Sanofi use?

Sanofi's detected technology footprint includes Meteor, Sei, Saviynt, Rave, Postman, Empower 3 Software. The full profile lists additional verified technologies when available.

Company profile

Pharmaceutical Manufacturing

Sanofi - Company Intelligence Profile

Industry: Pharmaceutical Manufacturing | Founded: not publicly disclosed | HQ: Paris, France

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth.

Datakart tracks firmographic, hiring, traffic, technology, funding, review, and leadership signals for Sanofi to help teams evaluate the account with useful business context.

Public Company

Sanofi

sanofi.com

Employees

92.8K

Monthly visits

917K

Open roles

1.3K

Search volume

49.5K

View intelligence Start free trial

Company Snapshot

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth.

We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.

Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

N/A

Founded

92.8K

Employee count

917K

Monthly website visits

1.3K

Open roles

Company Snapshot Details

Legal name: Sanofi

Headquarters: Paris, France

Industry: Pharmaceutical Manufacturing

Sub-sector: Pharmaceutical Manufacturing

Website: https://www.sanofi.com

YoY headcount growth: not publicly disclosed

Company stage: Public Company

Last updated: Wed, 29 Apr 2026

Company intelligence

Business signals that help qualify Sanofi

This profile combines firmographic, traffic, hiring, employee, review, compensation, technology, funding, leadership, and product availability signals so visitors can answer practical business questions without hunting across multiple data sources.

Source snapshot

Last refreshed 2026-04-29 | 50K search volume | Domain sanofi.com

Annual revenue

$42.4B

Reported annual revenue from the source dataset when available.

Quarterly revenue

EUR 12.4B

Standalone quarterly revenue field from the source dataset.

Monthly visits

917K

Latest monthly visits value available from the source dataset.

Global web rank

#57,279

Lower rank values indicate stronger web visibility in the source dataset.

Employees

92.8K

Latest employees value available from the source dataset.

+114 monthly (+9.3%)

Hiring demand

1.3K

Open roles reveal which teams may be expanding and where vendor demand can emerge. For Sanofi, this signal is based on the latest available source snapshot.

+249 monthly (+0.3%)

Headcount momentum

92.8K

Recent employee count movement helps qualify growth, contraction, and operational scale. For Sanofi, this signal is based on the latest available source snapshot.

+44.3K monthly (+0.9%)

Audience growth

4.9M

LinkedIn follower movement is a useful proxy for employer brand, market attention, and hiring reach. For Sanofi, this signal is based on the latest available source snapshot.

+38.6K monthly (+4.4%)

Web demand

917K

Website traffic movement helps benchmark customer interest and go-to-market momentum. For Sanofi, this signal is based on the latest available source snapshot.

Identity atlas

Sanofi identity, aliases, ownership, and taxonomy

This section makes the entity easier to verify: canonical domains, alternate names, descriptions, ownership flags, parent or acquirer context, industry codes, and source-level social reach are grouped together.

Company descriptions

All available company description fields from the source dataset.

Company descriptiondescription

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Enriched descriptionDescription Enriched

Sanofi is an innovative global healthcare company with one purpose: to chase the miracles of science to improve people's lives.

Metadata descriptionDescription Metadata Raw

We are an innovative global healthcare company with one purpose: to chase the miracles of science to improve people’s lives.

LinkedIn followers

4.9M

Latest linkedin followers value available from the source dataset.

Owler followers

30.5K

Latest owler followers value available from the source dataset.

Technologies detected

1.2K

Latest technologies detected value available from the source dataset.

Ownership and corporate structure

Ownership status, parent company, acquisition status, and public/B2B flags.

Operating status

Active

Independent Company

Company type

Public Company

type

Ownership status

Public

Ownership Status

Public company

Is Public

Aliases and domain variants

Company name aliases, website aliases, and canonical domain signals.

Company alias

sanofi

Company Name Alias

Website alias

https://www.sanofi.com

Website Alias

Website alias

https://www.sanofi.com/

Website Alias

Canonical website

https://www.sanofi.com

website

Website domain

sanofi.com

Website Domain

Unique website

Yes

Unique Website

Unique domain

Yes

Unique Domain

Expired domain

Expired Domain

LinkedIn shorthand

sanofi

Canonical LinkedIn Shorthand Name

Source ID

1642

Source ID

UUID

5VWTSQJ54C9KX0D91Q5T8PZ0BW

uuid

Industry classification codes

SIC, NAICS, industry, and keyword classification signals.

Industry

Pharmaceutical Manufacturing

industry

Categories and keywords

['healthcare', 'vaccines', 'rare diseases', 'rare blood disorders', 'neurology', 'immunology', 'oncology', 'diabetes', 'cardiovascular diseases', 'consumer healthcare', 'pharmaceutical company', 'innovative', 'global healthcare', 'science', "improve people's lives", 'health', 'biotech', 'drug-development', 'life-sciences', 'pharma', 'therapy']

Categories And Keywords

Social follower counts

Follower counts available across LinkedIn, Twitter, and Owler.

LinkedIn followers

4.9M

Followers Count LinkedIn

Owler followers

30.5K

Followers Count Owler

Company locations

Known company locations and office addresses.

Primary location

46 Avenue de la Grande-Armée; Paris, France 75017, FR

Office location

1 Discovery Dr; Swiftwater, PA 18370, US

Office location

Lützowstraße 107; Berlin, BE 10785, DE

Office location

Calle Aquilino de la Guardia & Calle 47; Panama City, Panama, PA

Office location

Francisco Garcia Cortinas 2357; Montevideo, 11300, UY

Office location

11 Beach Rd; Singapore, Singapore, SG

Office location

Avenida das Nacoes Unidas; Sao Paulo, SP 04794-000, BR

Office location

Praca Floriano, 19; Rio de Janeiro, RJ 20031-050, BR

Social profiles

Official and source-linked social profiles.

Website

https://www.sanofi.com

https://www.linkedin.com/company/sanofi

Facebook

https://www.facebook.com/sanofi

Twitter / X

https://www.twitter.com/sanofi

Instagram

https://www.instagram.com/sanofi

YouTube

https://www.youtube.com/user/sanofiaventistven

TikTok

https://www.tiktok.com/@sanofi

Company contact points

Public company-level contact points available in the source dataset.

Phone

33-1-53-77-40-00

Financial intelligence

Sanofi revenue, funding, IPO, and acquisition history

Financial signals are grouped as an analyst-style view: revenue sources, income statement rows, funding rounds, acquisition activity, IPO fields, stock listing context, and ownership structure.

Annual revenue

$42.4B

Reported annual revenue from the source dataset when available.

Quarterly revenue

EUR 12.4B

Standalone quarterly revenue field from the source dataset.

Total disclosed funding

$11.7B

Sum of disclosed funding round amounts available in the source dataset.

Funding rounds

Number of funding rounds captured in the source dataset.

Acquisitions captured

109

Number of acquisition records captured across the available source columns.

Revenue signals

Annual, quarterly, and range-based revenue signals available in the source dataset.

Source 5

$42.4B

Annual revenue

Source 1EUR 45.4B

Standalone quarterly revenueEUR 12.4B

IPO and stock listing

IPO date, share price, exchange tickers, and public market identifiers.

Stock ticker

SAN.PA

Stock tickerSAN

Latest closing priceEUR 100.04

Ownership and corporate structure

Ownership status, parent company, acquisition status, and public/B2B flags.

Operating status

Active

Independent Company

Company type

Public Company

type

Ownership status

Public

Ownership Status

Public company

Is Public

Income statement rows

Income statement rows with revenue and profitability metrics where available.

FY, 2025

Fiscal Year

Primary value

Revenue: EUR 45.4B

Additional metrics

Gross profit: EUR 37.6B; EBITDA: EUR 14.3B; EBIT: EUR 9.3B; Net income: EUR 8B; Operating expense: EUR 26B; Gross margin: 82.9%; EBITDA margin: 31.6%

Q3, 2025

Primary value

Revenue: EUR 12.4B

Additional metrics

Gross profit: EUR 10.1B; EBITDA: EUR 4.1B; EBIT: EUR 3.6B; Net income: EUR 2.8B; Operating expense: EUR 6B; Gross margin: 80.9%; EBITDA margin: 33.0%

Q2, 2025

Primary value

Revenue: EUR 11.7B

Additional metrics

Gross profit: EUR 12.5B; EBITDA: EUR 5.2B; EBIT: EUR 4.5B; Net income: EUR 4.1B; Operating expense: EUR 7.4B; Gross margin: 1.1%; EBITDA margin: 43.9%

Q1, 2025

Primary value

Revenue: EUR 9.9B

Additional metrics

Gross profit: EUR 8B; EBITDA: EUR 2.7B; EBIT: EUR 2.3B; Net income: EUR 1.7B; Operating expense: EUR 5.3B; Gross margin: 81.3%; EBITDA margin: 27.4%

FY, 2024

Fiscal Year

Primary value

Revenue: EUR 46.1B

Additional metrics

Gross profit: EUR 38.9B; EBITDA: EUR 10.9B; EBIT: EUR 7.6B; Net income: EUR 5.6B; Operating expense: EUR 28B; Gross margin: 84.3%; EBITDA margin: 23.7%

Q3, 2024

Primary value

Revenue: EUR 13.4B

Additional metrics

Gross profit: EUR 10.3B; EBITDA: EUR 4.3B; EBIT: EUR 3.6B; Net income: EUR 2.8B; Operating expense: EUR 6B; Gross margin: 76.3%; EBITDA margin: 32.0%

Q2, 2024

Primary value

Revenue: EUR 10.7B

Additional metrics

Gross profit: EUR 8.2B; EBITDA: EUR 1.8B; EBIT: EUR 1.6B; Net income: EUR 1.1B; Operating expense: EUR 6.4B; Gross margin: 76.6%; EBITDA margin: 16.9%

Q1, 2024

Primary value

Revenue: EUR 10.5B

Additional metrics

Gross profit: EUR 8.1B; EBITDA: EUR 2B; EBIT: EUR 1.4B; Net income: EUR 1.2B; Operating expense: EUR 6.1B; Gross margin: 77.8%; EBITDA margin: 19.1%

FY, 2023

Fiscal Year

Primary value

Revenue: EUR 43.1B

Additional metrics

Gross profit: EUR 34.5B; EBITDA: EUR 12B; EBIT: EUR 7.9B; Net income: EUR 5.6B; Operating expense: EUR 22.6B; Gross margin: 80.2%; EBITDA margin: 27.8%

Q3, 2023

Primary value

Revenue: EUR 12B

Additional metrics

Gross profit: EUR 9.3B; EBITDA: EUR 3.8B; EBIT: EUR 3.2B; Net income: EUR 2.5B; Operating expense: EUR 5.5B; Gross margin: 77.5%; EBITDA margin: 31.6%

Q2, 2023

Primary value

Revenue: EUR 10B

Additional metrics

Gross profit: EUR 7.7B; EBITDA: EUR 2.5B; EBIT: EUR 1.9B; Net income: EUR 1.5B; Operating expense: EUR 5.2B; Gross margin: 77.1%; EBITDA margin: 25.0%

Q1, 2023

Primary value

Revenue: EUR 10.2B

Additional metrics

Gross profit: EUR 8.2B; EBITDA: EUR 3B; EBIT: EUR 2.5B; Net income: EUR 2B; Operating expense: EUR 5.3B; Gross margin: 80.4%; EBITDA margin: 29.0%

Period	Primary value	Additional metrics
FY, 2025 Fiscal Year	Revenue: EUR 45.4B	Gross profit: EUR 37.6B; EBITDA: EUR 14.3B; EBIT: EUR 9.3B; Net income: EUR 8B; Operating expense: EUR 26B; Gross margin: 82.9%; EBITDA margin: 31.6%
Q3, 2025 Q3	Revenue: EUR 12.4B	Gross profit: EUR 10.1B; EBITDA: EUR 4.1B; EBIT: EUR 3.6B; Net income: EUR 2.8B; Operating expense: EUR 6B; Gross margin: 80.9%; EBITDA margin: 33.0%
Q2, 2025 Q2	Revenue: EUR 11.7B	Gross profit: EUR 12.5B; EBITDA: EUR 5.2B; EBIT: EUR 4.5B; Net income: EUR 4.1B; Operating expense: EUR 7.4B; Gross margin: 1.1%; EBITDA margin: 43.9%
Q1, 2025 Q1	Revenue: EUR 9.9B	Gross profit: EUR 8B; EBITDA: EUR 2.7B; EBIT: EUR 2.3B; Net income: EUR 1.7B; Operating expense: EUR 5.3B; Gross margin: 81.3%; EBITDA margin: 27.4%
FY, 2024 Fiscal Year	Revenue: EUR 46.1B	Gross profit: EUR 38.9B; EBITDA: EUR 10.9B; EBIT: EUR 7.6B; Net income: EUR 5.6B; Operating expense: EUR 28B; Gross margin: 84.3%; EBITDA margin: 23.7%
Q3, 2024 Q3	Revenue: EUR 13.4B	Gross profit: EUR 10.3B; EBITDA: EUR 4.3B; EBIT: EUR 3.6B; Net income: EUR 2.8B; Operating expense: EUR 6B; Gross margin: 76.3%; EBITDA margin: 32.0%
Q2, 2024 Q2	Revenue: EUR 10.7B	Gross profit: EUR 8.2B; EBITDA: EUR 1.8B; EBIT: EUR 1.6B; Net income: EUR 1.1B; Operating expense: EUR 6.4B; Gross margin: 76.6%; EBITDA margin: 16.9%
Q1, 2024 Q1	Revenue: EUR 10.5B	Gross profit: EUR 8.1B; EBITDA: EUR 2B; EBIT: EUR 1.4B; Net income: EUR 1.2B; Operating expense: EUR 6.1B; Gross margin: 77.8%; EBITDA margin: 19.1%
FY, 2023 Fiscal Year	Revenue: EUR 43.1B	Gross profit: EUR 34.5B; EBITDA: EUR 12B; EBIT: EUR 7.9B; Net income: EUR 5.6B; Operating expense: EUR 22.6B; Gross margin: 80.2%; EBITDA margin: 27.8%
Q3, 2023 Q3	Revenue: EUR 12B	Gross profit: EUR 9.3B; EBITDA: EUR 3.8B; EBIT: EUR 3.2B; Net income: EUR 2.5B; Operating expense: EUR 5.5B; Gross margin: 77.5%; EBITDA margin: 31.6%
Q2, 2023 Q2	Revenue: EUR 10B	Gross profit: EUR 7.7B; EBITDA: EUR 2.5B; EBIT: EUR 1.9B; Net income: EUR 1.5B; Operating expense: EUR 5.2B; Gross margin: 77.1%; EBITDA margin: 25.0%
Q1, 2023 Q1	Revenue: EUR 10.2B	Gross profit: EUR 8.2B; EBITDA: EUR 3B; EBIT: EUR 2.5B; Net income: EUR 2B; Operating expense: EUR 5.3B; Gross margin: 80.4%; EBITDA margin: 29.0%

Funding rounds

Funding history and recent round context.

Post-IPO Debt

$3B

2025-11-28

Post-IPO Debt

$3B

2025-10-01

Post-IPO Debt

EUR 1.5B

2025-06-01

Post-IPO Debt

EUR 1.5B

2025-03-01 | Deutsche Bank, ING Group, JP Morgan, Santander CIB

Post-IPO Equity

$329M

2022-03-15 | Blackstone Life Sciences

Grant

$2B

2020-07-01 | HHS Administration for Strategic Preparedness and Response

Grant

$30.8M

2020-04-01 | HHS Administration for Strategic Preparedness and Response

Post-IPO Equity

$310M

2014-12-02 | Evotec

Post-IPO Equity

2002-07-01

Corporate Round

1999-05-01 | Synthélabo

Corporate Round

1973-02-01 | Elf

Post-IPO Debt

Acquisitions and corporate activity

Acquisitions and corporate activity captured in the source dataset.

Dynavax Technologies Corp.

$2.2B

2025-12-01 | Acquisition List Source 5

ViceBio Limited

$1.1B

2025-07-01 | Acquisition List Source 5

Blueprint Medicines Corporation

$9.5B

2025-06-01 | Acquisition List Source 5

Vigil Neuroscience, Inc.

$470M

2025-05-01 | Acquisition List Source 5

Inhibrx, Inc

$1.7B

2024-05-30 | Acquisition List Source 1

Inhibrx, Inc.

$1.7B

2024-01-01 | Acquisition List Source 5

Qunol

Acquisition

2023-07-28 | Acquisition List Source 1

Qunol

Acquisition

2023-07-01 | Acquisition List Source 5

Provention Bio

$2.9B

2023-03-13 | Acquisition List Source 1

Provention Bio, Inc.

$2.9B

2023-03-01 | Acquisition List Source 5

Amunix

$1B

2021-12-20 | Acquisition List Source 1

Origimm

Acquisition

2021-12-01 | Acquisition List Source 1

Amunix Pharmaceuticals, Inc.

$1B

2021-12-01 | Acquisition List Source 5

Origimm Biotechnology GmbH

Acquisition

2021-12-01 | Acquisition List Source 5

Kadmon

$1.9B

2021-09-08 | Acquisition List Source 1

Translate Bio

$3.2B

2021-08-03 | Acquisition List Source 1

Tidal Therapeutics

$160M

2021-04-09 | Acquisition List Source 1

Kymab

$1.1B

2021-01-11 | Acquisition List Source 1

Kiadis Pharma

EUR 308M

2020-11-02 | Acquisition List Source 1

Principia BioPharma

$3.4B

2020-08-17 | Acquisition List Source 1

Synthorx

$2.5M

2019-12-09 | Acquisition List Source 1

Ablynx

$4.8B

2018-01-29 | Acquisition List Source 1

Bioverativ

$11.6B

2018-01-22 | Acquisition List Source 1

Aventis S.A.

Acquisition

2004-08-30 | Acquisition List Source 1

Sanofi Pasteur Europe

Acquisition

Acquisition List Source 1

Sanofi Finance Ireland limited

Acquisition

Acquisition List Source 1

Sanofi-Aventis de Chile S.A.

Acquisition

Acquisition List Source 1

Aventis Pharma Holdings Ltd

Acquisition

Acquisition List Source 1

Sanofi Produtos Farmaceuticos Lda

Acquisition

Acquisition List Source 1

Sanofi Investment Co., Ltd

Acquisition

Acquisition List Source 1

Sanofi-Aventis Israël Ltd

Acquisition

Acquisition List Source 1

Sanofi-Aventis South Africa (Pty) Ltd

Acquisition

Acquisition List Source 1

Sanofi Pasteur Ltd

Acquisition

Acquisition List Source 1

Genzyme Flanders BVBA

Acquisition

Acquisition List Source 1

Sanofi K.K.

Acquisition

Acquisition List Source 1

EUROAPI

Acquisition

Acquisition List Source 1

Aventis Pharma (Manufacturing) Pte. Ltd

Acquisition

Acquisition List Source 1

Sanofi-Aventis, s.r.o.

Acquisition

Acquisition List Source 1

Sanofi India Limited

Acquisition

Acquisition List Source 1

Sanofi-aventis Vietnam Company Limited

Acquisition

Acquisition List Source 1

Sanofi-Aventis Argentina S.A.

Acquisition

Acquisition List Source 1

Ablynx N.V.

Acquisition

Acquisition List Source 1

Sanofi Pasteur Biologies Co., Ltd

Acquisition

Acquisition List Source 1

Sanofi Egypt

Acquisition

Acquisition List Source 1

RPR US Ltd.

Acquisition

Acquisition List Source 1

Sanofi-Aventis Participations

Acquisition

Acquisition List Source 1

Kadmon Corporation, LLC

Acquisition

Acquisition List Source 1

Sanofi-Aventis de Colombia S.A.

Acquisition

Acquisition List Source 1

A. Nattermann & Cie. GmbH

Acquisition

Acquisition List Source 1

Opella Healthcare International SAS

Acquisition

Acquisition List Source 1

Sanofi Pasteur NVL

Acquisition

Acquisition List Source 1

Sanofi-Aventis Private Co, Ltd

Acquisition

Acquisition List Source 1

EUROAPI Germany

Acquisition

Acquisition List Source 1

Sanofi Biotechnology

Acquisition

Acquisition List Source 1

Limited Liability Company Sanofi-Aventis Ukraine

Acquisition

Acquisition List Source 1

Sanofi 2015 D SAS

Acquisition

Acquisition List Source 1

Sanofi Saglik Urunleri Limited Sirketi

Acquisition

Acquisition List Source 1

Genzyme Europe B.V.

Acquisition

Acquisition List Source 1

Sanofi Healthcare India Private Limited

Acquisition

Acquisition List Source 1

Genzyme de Argentina S.A.

Acquisition

Acquisition List Source 1

EUROAPI Hungary Kft.

Acquisition

Acquisition List Source 1

Genzyme Therapeutic Products Limited Partnership

Acquisition

Acquisition List Source 1

Francopia

Acquisition

Acquisition List Source 1

Sanofi AB

Acquisition

Acquisition List Source 1

Sanofi Foreign Participations B.V

Acquisition

Acquisition List Source 1

Sanofi Pasteur S.A. de C.V.

Acquisition

Acquisition List Source 1

Euroapi UK Ltd.

Acquisition

Acquisition List Source 1

Sanofi-Aventis Canada Inc.

Acquisition

Acquisition List Source 1

Sanofi Hong-Kong Limited

Acquisition

Acquisition List Source 1

Sanofi-Aventis A.E.B.E.

Acquisition

Acquisition List Source 1

VaxServe, Inc.

Acquisition

Acquisition List Source 1

Sanofi-Aventis Winthrop S.A. de C.V.

Acquisition

Acquisition List Source 1

Opella Healthcare Hungary K.F.T

Acquisition

Acquisition List Source 1

Sanofi-Aventis Singapore Pte. Ltd

Acquisition

Acquisition List Source 1

Aventis Pharma S.A.

Acquisition

Acquisition List Source 1

Sanofi-aventis Holdings Ltd

Acquisition

Acquisition List Source 1

Chattem, Inc.

Acquisition

Acquisition List Source 1

PT Aventis Pharma

Acquisition

Acquisition List Source 1

Sanofi-Aventis de Venezuela S.A.

Acquisition

Acquisition List Source 1

Opella Healthcare France SAS

Acquisition

Acquisition List Source 1

Sanofi-Aventis Algérie

Acquisition

Acquisition List Source 1

Kiadis Pharma Holding B.V.

Acquisition

Acquisition List Source 1

Sanofi-Aventis Gulf FZE

Acquisition

Acquisition List Source 1

Carraig Insurance DAC

Acquisition

Acquisition List Source 1

Sanofi-Aventis GmbH

Acquisition

Acquisition List Source 1

Shanghai Rongheng Pharmaceutical Co, Ltd

Acquisition

Acquisition List Source 1

Chinoin Private Co. Ltd

Acquisition

Acquisition List Source 1

Sanofi US Services Inc.

Acquisition

Acquisition List Source 1

Sanofi Belgium

Acquisition

Acquisition List Source 1

Sanofi Arabia Trading Company Limited

Acquisition

Acquisition List Source 1

SSP Co.,Ltd

Acquisition

Acquisition List Source 1

Sanofi-Aventis Groupe

Acquisition

Acquisition List Source 1

Sanofi Vaccine Technologies

Acquisition

Acquisition List Source 1

Kiadis Pharma N.V

Acquisition

Acquisition List Source 1

Sanofi-Aventis Sp. z.o.o.

Acquisition

Acquisition List Source 1

Sanofi-Aventis U.S. LLC

Acquisition

Acquisition List Source 1

Sanofi Romania SRL

Acquisition

Acquisition List Source 1

Sanofi-Aventis Ltd

Acquisition

Acquisition List Source 1

Sanofi-Aventis de Panama S.A.

Acquisition

Acquisition List Source 1

Sanofi Pasteur Asi Ticaret A.S.

Acquisition

Acquisition List Source 1

SECIPE SAS

Acquisition

Acquisition List Source 1

Sanofi-Aventis Maroc

Acquisition

Acquisition List Source 1

Sanofi Ilac Sanayi ve Ticaret A.S.

Acquisition

Acquisition List Source 1

Sanofi Nichi-Iko K.K.

Acquisition

Acquisition List Source 1

Sanofi Pharmaceuticals Co.Ltd

Acquisition

Acquisition List Source 1

Sanofi-Aventis de Mexico S.A. de C.V.

Acquisition

Acquisition List Source 1

sanofi-aventis Slovakia s.r.o.

Acquisition

Acquisition List Source 1

Aventisub LLC

Acquisition

Acquisition List Source 1

EUROAPI France

Acquisition

Acquisition List Source 1

Audience analytics

Web visibility, demand, and topics

Use these signals to understand discoverability, demand quality, search interest, and audience fit.

Monthly visits

917K

Latest monthly visits value available from the source dataset.

Global web rank

#57,279

Lower rank values indicate stronger web visibility in the source dataset.

Bounce rate

44.0%

Latest bounce rate value available from the source dataset.

Pages per visit

2.9

Latest pages per visit value available from the source dataset.

Average visit duration

2m 5s

Latest average visit duration value available from the source dataset.

Estimated monthly page views

2.7M

Derived estimate calculated as monthly visits multiplied by pages per visit.

Website visits

Website visits trend from the latest source snapshots.

LinkedIn followers

LinkedIn followers trend from the latest source snapshots.

Website visits by country

United States29.57

India12.21

France11.65

Canada7.44

Turkey3.6

Employees, hiring, attrition, and compensation

This section groups org scale, hiring motion, employee movement, department mix, and salary benchmarks so teams can qualify operating momentum and budget signals.

Employees

92.8K

Latest employees value available from the source dataset.

Inferred employees

60K

Latest inferred employees value available from the source dataset.

Open roles

1.3K

Latest open roles value available from the source dataset.

Departures

Latest departures value available from the source dataset.

Employee attrition rate

0.0%

Latest employee attrition rate value available from the source dataset.

Hiring intensity

14.4 roles / 1K employees

Derived signal showing open roles normalized by employee count.

Employee headcount

Employee headcount trend from the latest source snapshots.

Inferred employees

Inferred employees trend from the latest source snapshots.

Open job postings

Open job postings trend from the latest source snapshots.

Employee attrition rate

Employee attrition rate trend from the latest source snapshots.

Employee count by department

Other Department11.3K

Operations7.9K

Medical7.4K

Research5.9K

Sales5.9K

Technical4.7K

Project Management3.8K

Employee count by seniority

Specialist22.5K

Manager13.5K

Other Management12.7K

Senior5K

Head4.6K

Director2.6K

Intern1.2K

Employee count by region

Western Europe18.8K

Northern America14K

Southern Asia5.2K

Latin America4.9K

Southern Europe3.2K

Eastern Europe3K

Eastern Asia2.4K

Top employee countries

France14.5K

United States11.9K

India4.5K

Germany2.7K

Canada2.1K

Brazil1.8K

Hungary1.7K

Active job openings

Selected open roles that reveal current hiring demand.

Pharmaziepraktikant*in im Bereich Regulatory Affairs Artwork November 2026

Open role

4346924986

Technicien Production Vrac H/F

Open role

4354275464

Expert Scientific Writer- HEVA

Open role

4364964271

RWE Project Lead Analytics

Open role

4364968276

IFB-Quality Assurance Manager-QMS

Open role

4364969226

Internal Auditor

Open role

4365029618

Strategic Account Manager Los Angeles S, CA

Open role

4366227916

Senior Clinical Research Director - Oncology

Open role

4366971938

Showing 8 of 18 available records.

Where employees came from

Common previous employers visible in employee profile movement.

Pfizer

3.6K employee movements

Internal profile link

GSK

3.2K employee movements

Internal profile link

Novartis

3K employee movements

Internal profile link

Boehringer Ingelheim

2K employee movements

Internal profile link

AstraZeneca

1.9K employee movements

Internal profile link

Bristol Myers Squibb

1.5K employee movements

Internal profile link

Bayer

1.4K employee movements

Internal profile link

Roche

1.4K employee movements

Internal profile link

Showing 8 of 9 available records.

Where employees go next

Common next employers visible in employee profile movement.

Novartis

3.1K employee movements

Internal profile link

GSK

2.7K employee movements

Internal profile link

Pfizer

2.6K employee movements

Internal profile link

AstraZeneca

2.4K employee movements

Internal profile link

Opella

1.9K employee movements

Internal profile link

Boehringer Ingelheim

1.7K employee movements

Internal profile link

Roche

1.6K employee movements

Internal profile link

Bayer

1.5K employee movements

Internal profile link

Showing 8 of 10 available records.

Product and reputation

Product readiness, customer proof, and employee sentiment

Product availability, public reviews, and employee sentiment help visitors understand whether the company is mature, documented, reviewable, and operationally healthy.

Product availability Q&A

Buyer-facing product availability signals in question-and-answer format.

Is pricing information available?

No. The source snapshot does not list pricing information for this company.

Source availability signal

Is a free trial listed?

No. The source snapshot does not list a free trial for this company.

Source availability signal

Can buyers request a demo?

No. The source snapshot does not list a demo motion for this company.

Source availability signal

Is the product downloadable?

No. The source snapshot does not list downloadable software for this company.

Source availability signal

Are mobile apps listed?

No. The source snapshot does not list mobile apps for this company.

Source availability signal

Is public documentation listed?

No. The source snapshot does not list public documentation for this company.

Source availability signal

Are online reviews listed?

No. The source snapshot does not list online reviews for this company.

Source availability signal

Company graph

Technology, leadership, competitors, funding, and corporate activity

These data points help sales, partnerships, analysts, and researchers understand how the company operates, who surrounds it, and where it may be moving next.

Verified technologies

Detected tools and systems verified in the source dataset.

Meteor

Verified technology

Last verified 2026-05-04 | First seen 2025-08-17

Sei

Verified technology

Last verified 2026-05-04 | First seen 2025-08-17

Saviynt

Verified technology

Last verified 2026-05-04 | First seen 2025-11-03

Rave

Verified technology

Last verified 2026-05-04 | First seen 2025-08-17

Postman

Verified technology

Last verified 2026-05-04 | First seen 2024-05-20

Empower 3 Software

Verified technology

Last verified 2026-05-04 | First seen 2026-03-30

Rsa Archer

Verified technology

Last verified 2026-05-04 | First seen 2026-03-29

Packer

Verified technology

Last verified 2026-05-04 | First seen 2025-08-17

Showing 8 of 24 available records.

Market alternatives and competitors

Comparable companies surfaced by the source dataset.

Viatris

Comparable company

Market alternative

Abbvie

Comparable company

Market alternative

Lilly

Comparable company

Market alternative

Merck

Comparable company

Market alternative

Novartis

Comparable company

Market alternative

Teva Pharmaceuticals

Comparable company

Market alternative

Astrazeneca

Comparable company

Market alternative

Pfizer

Comparable company

Market alternative

Showing 8 of 12 available records.

Leadership and senior operators

Senior employees and operators visible in the source dataset.

Jean-Jacques Nguyen-Huu

Head Of Analytical Development - Pre Retired

Bernd Kuehn

Primary Container CoE Head Cartridge Platform Development

Pilsudski Richard

Vice President, Global Head General Medicines Business Unit, Global Regulatory Affairs

Ellery Jones

Associate Director Of Forecasting

Noelia Villarreal

HR Business Partner - Biopharma LATAM

James Kearns

Early-Stage Immunology Automation Lead Vaccines

Daniel Di Doménico

Senior Talent Acquisition Partner- North America

Alexandre Campos

Responsable De Maintenance Unité Conditionnement

Showing 8 of 12 available records.

Recent executive arrivals

Recent leadership and senior employee arrival signals.

Cristian Fernando Vargas Castillo

Head of Demand Planning Services

Jan 2026

Yunke Xiang

Head of Data & AI, Manufacturing & Supply (VP)

Apr 2026

Héloïse ARMAND

Head of Quality Dupixent Cluster

Jan 2026

Tanja Bader

Franchise Head Alliance Immunology GSA

Jan 2026

Rachel Gross

Corporate Communications Lead, Sanofi UKIE

Feb 2026

Sangeetha Panneru

Head of Master Data Management

Mar 2026

Vladimir Litvak

Distinguished Scientist and Section Head

Jan 2026

José Varde

Commercial Head Pharma - South Cone

Mar 2026

Recent executive departures

Recent leadership and senior employee departure signals.

Héloïse ARMAND

Head of Insulin Cluster Quality Operations

Feb 2026

Rachel Gross

Director, CEO & Executive Communications

Feb 2026

Leah Mancini

MSL Regional Director - NextGen Immunology GI

Mar 2026

Edwin Raaj

Lead Biotechnologist

Apr 2026

Océane BLAIN

R&D Project Leader

Dec 2025

Océane BLAIN

R&D Project Leader : Analytical method validation: monitoring bioprocess critical parameters

Dec 2025

Thibault CHARDAIRE

Formulation Laboratory Head

Jan 2026

Chiara Zilocchi

Oncology & Hematology Medical Lead

Jan 2026

Company locations

Known company locations and office addresses.

Primary location

46 Avenue de la Grande-Armée; Paris, France 75017, FR

Office location

1 Discovery Dr; Swiftwater, PA 18370, US

Office location

Lützowstraße 107; Berlin, BE 10785, DE

Office location

Calle Aquilino de la Guardia & Calle 47; Panama City, Panama, PA

Office location

Francisco Garcia Cortinas 2357; Montevideo, 11300, UY

Office location

11 Beach Rd; Singapore, Singapore, SG

Office location

Avenida das Nacoes Unidas; Sao Paulo, SP 04794-000, BR

Office location

Praca Floriano, 19; Rio de Janeiro, RJ 20031-050, BR

Recent company updates

Recent company update signals from the source dataset.

Un rendez-vous chez le dermato, mission im-peau-ssible ? 😎 En France, l’accès aux soins dermatologiques est…

260 reactions; 3 comments

2026-04-28 | Un rendez-vous chez le dermato, mission im-peau-ssible ? 😎 En France, l’accès aux soins dermatologiques est en crise. Avec une moyenne nationale de seulement 3,25 dermatologues pour 100 000 habitants, le système est s…

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has recommended for appro…

1.1K reactions; 15 comments

2026-04-24 | The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has recommended for approval our new investigational treatment for secondary progressive multiple sclerosis (SPMS) without relapses.…

More than a draw. A promise of inclusion. The draw for the Special Olympics Unified Football World Cup, whi…

176 reactions; 4 comments

2026-04-24 | More than a draw. A promise of inclusion. The draw for the Special Olympics Unified Football World Cup, which will bring together athletes with and without intellectual disabilities in Paris this coming July, revealed…

Our Q1 2026 results are now available. See the press release for more details: http://spkl.io/6048AfHP8 #S…

1.1K reactions; 2 comments

2026-04-23 | Our Q1 2026 results are now available. See the press release for more details: http://spkl.io/6048AfHP8 #SanofiResults

Our medicine has been approved by the FDA for certain children aged 2-11 years with uncontrolled chronic spon…

1.1K reactions; 13 comments

2026-04-22 | Our medicine has been approved by the FDA for certain children aged 2-11 years with uncontrolled chronic spontaneous urticaria (CSU). Learn more about this significant milestone: CC: Regeneron

Every day, we chase the miracles of science to improve people’s lives. But we don’t chase them alone. Behin…

293 reactions; 5 comments

2026-04-22 | Every day, we chase the miracles of science to improve people’s lives. But we don’t chase them alone. Behind every breakthrough is a team of people who see their work as more than a job, people who know that when pati…

Industry classification codes

SIC, NAICS, industry, and keyword classification signals.

Industry

Pharmaceutical Manufacturing

industry

Categories and keywords

Categories And Keywords

Public market signal

Sanofi stock snapshot

TradingView market widget for PA:SAN.

PA:SAN

Sanofi FAQs

Company profile

Want verified contact data for Sanofi?

Datakart.ai gives you verified email addresses, direct dials, and buying intent signals for key decision-makers at Sanofi and 1,700+ other companies.

Start your free trial Directory

Sanofi - Company Intelligence Profile

Company Snapshot

Company Snapshot Details

Business signals that help qualify Sanofi

Sanofi identity, aliases, ownership, and taxonomy

Sanofi revenue, funding, IPO, and acquisition history

Web visibility, demand, and topics

Employees, hiring, attrition, and compensation

Product readiness, customer proof, and employee sentiment

Technology, leadership, competitors, funding, and corporate activity

Sanofi FAQs

Company profile

Who are Sanofi's key investors?

How many employees does Sanofi have?

How much website traffic does Sanofi receive?

Is Sanofi currently hiring?

What technologies does Sanofi use?

Want verified contact data for Sanofi?